Atlas Trials

Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies

Clinical trial NCT04601181 · UNKNOWN

Trial details

NCT number
NCT04601181
Sponsor
Fundamenta Therapeutics, Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
B Cell Malignancy
Start date
2020-10-23
Primary completion
2022-10-15
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.